The non-exclusive licence is to further advance preclinical disease modelling
Photo as seen on ERS Genomics website
ERS Genomics Limited and Bioneer A/S have signed a license agreement providing Bioneer access to CRISPR/Cas9 genome editing technology intellectual property. Bioneer, a Denmark-based life science research and technology provider, will utilise CRISPR/Cas9 technology to generate a range of innovative human cell-based disease models.
Under the terms of the license, Bioneer is able to generate and commercialise CRISPR-edited cell-based models, broadening its core capabilities and expanding on Bioneer's expertise in biomedical research support.
Eric Rhodes, CEO of ERS Genomics, said: “Bioneer has proven expertise in a broad array of biomedical fields. Adding CRISPR/Cas9 to their toolbox ensures they remain on the leading edge of technology. We are very pleased that Bioneer chose to expand on its service offering by licensing CRISPR/Cas9 technology through ERS Genomics."
“This cutting-edge technology will complement Bioneer’s competencies in advanced preclinical disease modelling,” said Lars H Pedersen, CEO of Bioneer.
Christian Clausen, CSO of Bioneer, continued: “Bioneer is working with both industry and academia to solve complex disease relevant questions by using advanced disease modelling. The CRISPR/Cas9 tools will enable clients and collaborators to precisely tailor their preclinical modelling strategies to their specific needs for predictive in vitro models.